Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2479722rdf:typepubmed:Citationlld:pubmed
pubmed-article:2479722lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C0007137lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C0460004lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C0005740lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C1521750lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C0205179lld:lifeskim
pubmed-article:2479722lifeskim:mentionsumls-concept:C0919257lld:lifeskim
pubmed-article:2479722pubmed:issue5lld:pubmed
pubmed-article:2479722pubmed:dateCreated1990-1-4lld:pubmed
pubmed-article:2479722pubmed:abstractText29 evaluable patients with advanced and/or metastatic epidermoid carcinomas of the head and neck were treated with a combination of bleomycin, methotrexate and ftorafur. 3 complete remission, 12 partial remission (objective response 51.7%), 10 stable disease and 4 progressed disease were obtained, with the best responses in the oral cavity and skin carcinomas. The grade of performance status and the pretreatments affected the response, with a very high response rate in nonpretreated patients, where objective results were obtained in all cases. The toxicity was very mild. We believe that this combination can be recommended for epidermoid carcinomas of the skin and oral cavity, considering its high response rate, feasibility and low toxicity.lld:pubmed
pubmed-article:2479722pubmed:languageenglld:pubmed
pubmed-article:2479722pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2479722pubmed:citationSubsetIMlld:pubmed
pubmed-article:2479722pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2479722pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2479722pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2479722pubmed:statusMEDLINElld:pubmed
pubmed-article:2479722pubmed:monthOctlld:pubmed
pubmed-article:2479722pubmed:issn1120-009Xlld:pubmed
pubmed-article:2479722pubmed:authorpubmed-author:CostaGGlld:pubmed
pubmed-article:2479722pubmed:authorpubmed-author:AltavillaGGlld:pubmed
pubmed-article:2479722pubmed:authorpubmed-author:AdamsRRlld:pubmed
pubmed-article:2479722pubmed:authorpubmed-author:ScimoneAAlld:pubmed
pubmed-article:2479722pubmed:authorpubmed-author:CaristiNNlld:pubmed
pubmed-article:2479722pubmed:authorpubmed-author:AlafaciEElld:pubmed
pubmed-article:2479722pubmed:authorpubmed-author:ChiofaloGGlld:pubmed
pubmed-article:2479722pubmed:issnTypePrintlld:pubmed
pubmed-article:2479722pubmed:volume1lld:pubmed
pubmed-article:2479722pubmed:ownerNLMlld:pubmed
pubmed-article:2479722pubmed:authorsCompleteYlld:pubmed
pubmed-article:2479722pubmed:pagination338-41lld:pubmed
pubmed-article:2479722pubmed:dateRevised2009-8-4lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:meshHeadingpubmed-meshheading:2479722-...lld:pubmed
pubmed-article:2479722pubmed:year1989lld:pubmed
pubmed-article:2479722pubmed:articleTitleTreatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur.lld:pubmed
pubmed-article:2479722pubmed:affiliationIstituto di Clinica Oncologica e di Ricerca sui Tumori, Università di Messina, Italy.lld:pubmed
pubmed-article:2479722pubmed:publicationTypeJournal Articlelld:pubmed